State of Oklahoma Selects ERT's Suicide Risk Assessment System
The State of Oklahoma, Department of Mental Health and Substance Abuse Services will be implementing ERT's AVERT Suicide Risk Assessment
The State of Oklahoma, Department of Mental Health and Substance Abuse Services (ODMHSAS) will be implementing ERT's AVERT™ Suicide Risk Assessment (SRA) system as a key component in its development of a public health infrastructure that facilitates suicide prevention.
ODMHSAS has adopted the “Zero Suicides” approach endorsed by the Action Alliance for Suicide Prevention (www.zerosuicides.org), and has committed to having mental health patients proactively assessed for suicide risk. They have chosen the Columbia Suicide Severity Rating Scale (C-SSRS) for this task. AVERT has been used over 160,000 times to assess over 35,000 patients, and has shown to be a reliable, efficient, and scalable solution for SRA in clinical practice. AVERT electronically administers the assessments in audio or visual formats, enabling patients to comfortably and privately report their suicidal ideation and behaviors (SIB). AVERT will be used to collect the C-SSRS electronically (eC-SSRS) from mental health patients throughout the state.
“We are very pleased to embark on this partnership with ERT as a part of our Zero Suicide Initiative,” said Carrie Slatton-Hodges, Deputy Commissioner of Recovery and Treatment, Oklahoma Department of Mental Health and Substance Abuse Services. “We anticipate that with our planned spectrum of screening, assessment, and evidence based treatment utilizing the Collaborative Assessment and Management of Suicidality (CAMS) framework, many lives will be saved.”
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
